Cadila Healthcare Limited Mesalamine Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Mesalamine Export Records India — #3 Exporter, 32 Shipments, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Mesalamine

India Pharmaceutical Trade Intelligence

$1.3B103 Suppliers51 CountriesHS 30049099

ExportsIndia → UNITED STATES98.6%India → RUSSIA0.4%

ImportsUNITED STATES → India$1.0M ISRAEL → India$27.3K

#1 Supplier: ZYDUS LIFESCIENCES #1 Buyer: EVERSANA LIFE

Cadila Healthcare Limited — Mesalamine Exporter #3 | $2.0M Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Mesalamine Exporter Profile

Indian Pharmaceutical Exporter · #3 for Mesalamine · $2.0M export value · DGFT Verified

Cadila Healthcare Limited is the #3 Indian exporter of Mesalamine with $2.0M in export value and 32 verified shipments. Cadila Healthcare Limited holds a 0.1% market share in Mesalamine exports across 1 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Mesalamine Export Profile: Buyers & Destinations

Cadila Healthcare Limited Mesalamine export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Mesalamine?

Country	Value	Shipments	Share
UNITED STATES	$43.8M	875	85.8%
RUSSIA	$1.9M	38	3.7%
MEXICO	$950.0K	19	1.9%
BRAZIL	$850.0K	17	1.7%

Who Are the Top Buyers of Mesalamine from India?

Buyer	Country	Value	Orders
EVERSANA LIFE SCIENCE SERVICES	UNITED STATES	$15.8M	317
NORTHSTAR DISTRIBUTION CENTER 8912	UNITED STATES	$3.1M	63
SUN PHARMACEUTICAL INDUSTRIES,INC.	UNITED STATES	$2.1M	42
SUN PHARMACEUTICAL INDUSTRIES INC	UNITED STATES	$1.9M	37
AO RANBAXY	RUSSIA	$1.2M	24
SUN PHARMACEUTICAL INDUSTRIES, INC.	UNITED STATES	$750.0K	15
AO "RANBAXY"	RUSSIA	$600.0K	12
EVERSANA LIFE SCIENCE SERVICES,	UNITED STATES	$200.0K	4
XXN PXXRMAXXUTIXXL IXXUSTXXES XXC	UNITED STATES	$150.0K	3
NORTHSTAR DISTRIBUTION CENTER	UNITED STATES	$150.0K	3

India's Mesalamine is purchased by 214 buyers worldwide. The top buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by NORTHSTAR DISTRIBUTION CENTER 8912 and SUN PHARMACEUTICAL INDUSTRIES,INC..

How Does Cadila Healthcare Limited Compare to Nearest Mesalamine Exporters?

Exporters ranked immediately above and below #3 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
8	ALKEM LABORATORIES LIMITED	$2.6M	52	1	$50.0K
9	ENCUBE ETHICALS PRIVATE LIMITED	$2.6M	80	1	$32.2K
3	CADILA HEALTHCARE LIMITED ★	$1.6M	32	1	$50.0K
11	ALEMBIC PHARMACEUTICALS LIMITED	$1.1M	38	1	$29.9K
6	SUN PHARMACEUTICAL INDUSTRIES LTD	$750.0K	15	2	$50.0K

Cadila Healthcare Limited ranks #3 among 103 Indian Mesalamine exporters. Average shipment value of $50.0K compared to the market average of $469.7K. The closest competitors by value are ALKEM LABORATORIES LIMITED and ENCUBE ETHICALS PRIVATE LIMITED.

Which Indian Ports Ship Mesalamine Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	801	21.2%
SAHAR AIR	789	20.9%
DELHI AIR	494	13.1%
SAHAR AIR CARGO ACC (INBOM4)	415	11.0%
MUNDRA SEA	134	3.5%
Delhi Air	131	3.5%
Bombay Air	120	3.2%
NHAVA SHEVA SEA (INNSA1)	70	1.9%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Mesalamine Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Mesalamine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 51+ countries, 214+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Mesalamine

Mesalamine

Cadila Healthcare Limited — Mesalamine Exporter Profile

Cadila Healthcare Limited — Mesalamine Export Profile: Buyers & Destinations

Where Does India Export Mesalamine?

Who Are the Top Buyers of Mesalamine from India?

What Is India's Total Mesalamine Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Mesalamine Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Mesalamine Exporters?

Regulatory Requirements: Exporting Mesalamine to Key Markets

United States — FDA

Mexico — COFEPRIS

How Does Cadila Healthcare Limited Compare to Nearest Mesalamine Exporters?

Which Indian Ports Ship Mesalamine Exports?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Mesalamine Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Mesalamine Export Data from Cadila Healthcare Limited

Mesalamine Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source